Log In
BCIQ
Print this Print this
 

MOR03087, MOR202

  Manage Alerts
Collapse Summary General Information
Company MorphoSys AG
DescriptionHuman HuCAL IgG1 mAb against CD38
Molecular Target CD38
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat multiple myeloma (MM); Treat relapsed or refractory multiple myeloma (MM)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$823.2M

$92.0M

$669.7M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/01/2013

$823.2M

$92.0M

$669.7M

Get a free BioCentury trial today